DK1495023T3 - Hidtil ukendte derivater af 1,2,3-substitueret indolizin, FGF-inhibitorer, fremgangsmåde for fremstilling og farmaceutiske sammensætninger indeholdende disse - Google Patents

Hidtil ukendte derivater af 1,2,3-substitueret indolizin, FGF-inhibitorer, fremgangsmåde for fremstilling og farmaceutiske sammensætninger indeholdende disse

Info

Publication number
DK1495023T3
DK1495023T3 DK03730302T DK03730302T DK1495023T3 DK 1495023 T3 DK1495023 T3 DK 1495023T3 DK 03730302 T DK03730302 T DK 03730302T DK 03730302 T DK03730302 T DK 03730302T DK 1495023 T3 DK1495023 T3 DK 1495023T3
Authority
DK
Denmark
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
new derivatives
substituted indolizine
Prior art date
Application number
DK03730302T
Other languages
English (en)
Inventor
Alain Badorc
Francoise Bono
Marie-Francoise Bordes
Nathalie Guillo
Jean-Marc Herbert
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of DK1495023T3 publication Critical patent/DK1495023T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK03730302T 2002-04-04 2003-04-02 Hidtil ukendte derivater af 1,2,3-substitueret indolizin, FGF-inhibitorer, fremgangsmåde for fremstilling og farmaceutiske sammensætninger indeholdende disse DK1495023T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0204220A FR2838123B1 (fr) 2002-04-04 2002-04-04 Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf

Publications (1)

Publication Number Publication Date
DK1495023T3 true DK1495023T3 (da) 2005-12-27

Family

ID=28052118

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03730302T DK1495023T3 (da) 2002-04-04 2003-04-02 Hidtil ukendte derivater af 1,2,3-substitueret indolizin, FGF-inhibitorer, fremgangsmåde for fremstilling og farmaceutiske sammensætninger indeholdende disse

Country Status (33)

Country Link
US (2) US7442708B2 (da)
EP (1) EP1495023B1 (da)
JP (1) JP4741799B2 (da)
KR (1) KR101022138B1 (da)
CN (1) CN100413863C (da)
AR (1) AR040404A1 (da)
AT (1) ATE304013T1 (da)
AU (1) AU2003240984B2 (da)
BR (1) BR0309026A (da)
CA (1) CA2476056C (da)
CO (1) CO5631442A2 (da)
DE (1) DE60301570T2 (da)
DK (1) DK1495023T3 (da)
EA (1) EA007902B1 (da)
EC (1) ECSP045338A (da)
ES (1) ES2247540T3 (da)
FR (1) FR2838123B1 (da)
HR (1) HRP20040912B1 (da)
IL (2) IL163755A0 (da)
IS (1) IS2475B (da)
MA (1) MA27297A1 (da)
ME (2) MEP22508A (da)
MX (1) MXPA04009639A (da)
NO (1) NO329025B1 (da)
NZ (1) NZ534786A (da)
PL (1) PL215265B1 (da)
RS (1) RS51399B (da)
SI (1) SI1495023T1 (da)
TN (1) TNSN04188A1 (da)
TW (1) TWI335222B (da)
UA (1) UA78016C2 (da)
WO (1) WO2003084956A1 (da)
ZA (1) ZA200406613B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
KR101279748B1 (ko) * 2003-11-04 2013-07-04 가부시키가이샤 디나벡크 겐큐쇼 유전자 도입된 수상세포의 제조방법
FR2865934B1 (fr) * 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
EP1775343A4 (en) * 2004-06-24 2007-11-14 Dnavec Research Inc ANTITUM-AGENT WITH DENDRITIC CELL WITH THE TRANSFECTED RNA VIRUS
JP2008520719A (ja) * 2004-11-22 2008-06-19 スレショルド ファーマシューティカルズ インコーポレイティッド チューブリン結合抗癌剤およびそれらのプロドラッグ
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (en) * 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
JP5552121B2 (ja) * 2008-09-04 2014-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のインドリジン阻害剤
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
EP2270043A1 (en) * 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
CN101648953B (zh) * 2009-09-24 2012-09-05 绍兴文理学院 一种咪唑并[1，2-b]吡咯并[1，2-f]哒嗪衍生物及其制备方法和用途
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2967412B1 (fr) * 2010-11-17 2012-12-14 Sanofi Aventis Nouveaux derives d'indolizine, leur preparation et leur application en therapeutique
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
WO2016093285A1 (ja) * 2014-12-10 2016-06-16 小野薬品工業株式会社 ジヒドロインドリジノン誘導体
EP3318563A1 (en) * 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN108864083B (zh) * 2018-06-07 2021-05-25 广东药科大学 一类具有抗癌活性的氨基取代吲嗪类化合物及其衍生物
CN110251513A (zh) * 2019-07-03 2019-09-20 南京大学 一种含吡唑的中氮茚化合物在制备抗肿瘤药物中的应用
US11976066B1 (en) 2023-10-23 2024-05-07 King Faisal University Substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates as anti-tubercular agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
US4378362A (en) * 1979-12-06 1983-03-29 S.A. Labaz N.V. Indolizine derivatives and process for preparing the same
FR2528845A1 (fr) * 1982-06-17 1983-12-23 Sanofi Sa Nouveaux derives d'indolizine, leur procede de preparation ainsi que les compositions therapeutiques les contenant
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
GB9318790D0 (en) * 1993-09-10 1993-10-27 Fujisawa Pharmaceutical Co Heterocyclic derivatives
IL144977A0 (en) * 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
DE60213802T2 (de) * 2001-06-06 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Cak inhibitoren und deren verwendungen
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
SI1495023T1 (sl) 2005-12-31
CA2476056C (fr) 2012-03-06
US7442708B2 (en) 2008-10-28
IL163755A0 (en) 2005-12-18
EA200400994A1 (ru) 2005-06-30
NO20044156L (no) 2005-01-03
JP4741799B2 (ja) 2011-08-10
ES2247540T3 (es) 2006-03-01
US20050203126A1 (en) 2005-09-15
ECSP045338A (es) 2005-03-10
PL215265B1 (pl) 2013-11-29
MA27297A1 (fr) 2005-05-02
IS7413A (is) 2004-08-19
WO2003084956A1 (fr) 2003-10-16
HRP20040912B1 (hr) 2012-10-31
EP1495023B1 (fr) 2005-09-07
DE60301570T2 (de) 2006-05-18
IL163755A (en) 2010-11-30
JP2005532286A (ja) 2005-10-27
AR040404A1 (es) 2005-04-06
NO329025B1 (no) 2010-08-02
HRP20040912A2 (en) 2004-12-31
US20090023770A1 (en) 2009-01-22
KR101022138B1 (ko) 2011-03-17
AU2003240984A1 (en) 2003-10-20
NZ534786A (en) 2006-06-30
CN100413863C (zh) 2008-08-27
RS86404A (sr) 2006-12-15
BR0309026A (pt) 2005-02-09
AU2003240984B2 (en) 2008-07-31
KR20040099388A (ko) 2004-11-26
CA2476056A1 (fr) 2003-10-16
HK1074631A1 (zh) 2005-11-18
ZA200406613B (en) 2007-12-27
FR2838123B1 (fr) 2005-06-10
RS51399B (sr) 2011-02-28
CN1649867A (zh) 2005-08-03
TW200306181A (en) 2003-11-16
CO5631442A2 (es) 2006-04-28
UA78016C2 (uk) 2007-02-15
MEP22508A (en) 2010-06-10
EP1495023A1 (fr) 2005-01-12
TWI335222B (en) 2011-01-01
ATE304013T1 (de) 2005-09-15
US7803811B2 (en) 2010-09-28
MXPA04009639A (es) 2005-07-13
EA007902B1 (ru) 2007-02-27
FR2838123A1 (fr) 2003-10-10
TNSN04188A1 (fr) 2007-03-12
DE60301570D1 (de) 2005-10-13
ME00118B (me) 2010-10-10
PL372812A1 (en) 2005-08-08
IS2475B (is) 2008-12-15

Similar Documents

Publication Publication Date Title
IS2475B (is) Nýjar 1,2,3,-setnar indólísín afleiður, hindrar af FGFS, aðferð við framleiðslu á þeim og lyfjafræðilegar samsetningar sem innihalda þau
IL190218A0 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HUP0104204A3 (en) Pyrazolopyridine derivatives as cox-2 inhibitors, process for their preparation and pharmaceutical compositions thereof
IS7735A (is) Bensódíasepín afleiður og lyfjasamsetningar sem innihalda þær.
HUP0303146A3 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
HUP0402554A3 (en) Condensated heterocyclic succinimide compounds, their use, process for the preparation of some of them and pharmaceutical compositions containing the compounds
HUP0400194A3 (en) Imidazolidindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
IS7543A (is) Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
HUP0402161A3 (en) Nicotin-or isonicotin benzothiazole derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0400193A3 (en) Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
HUP0401499A3 (en) Indole derivatives as cox ii inhibitors, process for their preparation and pharmaceutical compositions containing them
AU2003269421A8 (en) Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
NO20042272L (no) Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister
DK1558612T3 (da) Imidazopyridinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO20016404L (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20015659D0 (no) Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
DK1117661T3 (da) Propanolaminderivater substitueret med heterocycliske grupper, fremgangsmåde til deres fremstilling, farmaceutiske præparater indeholdende disse forbindelser og deres anvendelse
ZA200500203B (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HUP0400317A3 (en) Beta-carboline derivatives, process for their preparation, their use and pharmaceutical compositions containing them
IS7424A (is) Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
NO20031396D0 (no) Derivater av tryptamin og analoge sammensetninger, og farmasöytiske formuleringer som inneholder disse
DK1275647T3 (da) Octahydro-1H-pyrido[1,2-a]pyrazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
HUP0401280A3 (en) Pyrimidine derivatives useful as selective cox-2 inhibitors, process for their preparation and pharmaceutical compositions containing them
IS6063A (is) Nýjar morfólínafleiður, aðferð til framleiðslu þeirra og lyfjablöndur sem innihalda þessar afleiður